These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 21084276)
1. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Lopez G; Torres K; Liu J; Hernandez B; Young E; Belousov R; Bolshakov S; Lazar AJ; Slopis JM; McCutcheon IE; McConkey D; Lev D Cancer Res; 2011 Jan; 71(1):185-96. PubMed ID: 21084276 [TBL] [Abstract][Full Text] [Related]
2. Autophagy blockade enhances HDAC inhibitors' pro-apoptotic effects: potential implications for the treatment of a therapeutic-resistant malignancy. Lopez G; Torres K; Lev D Autophagy; 2011 Apr; 7(4):440-1. PubMed ID: 21224727 [TBL] [Abstract][Full Text] [Related]
3. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Ghadimi MP; Lopez G; Torres KE; Belousov R; Young ED; Liu J; Brewer KJ; Hoffman A; Lusby K; Lazar AJ; Pollock RE; Lev D Mol Cancer Ther; 2012 Aug; 11(8):1758-69. PubMed ID: 22848094 [TBL] [Abstract][Full Text] [Related]
4. Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors. Lopez G; Pollock RE Methods Mol Biol; 2017; 1510():365-374. PubMed ID: 27761835 [TBL] [Abstract][Full Text] [Related]
5. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. Peacock JD; Cherba D; Kampfschulte K; Smith MK; Monks NR; Webb CP; Steensma M J Transl Med; 2013 Sep; 11():213. PubMed ID: 24040940 [TBL] [Abstract][Full Text] [Related]
7. Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors. Chau V; Lim SK; Mo W; Liu C; Patel AJ; McKay RM; Wei S; Posner BA; De Brabander JK; Williams NS; Parada LF; Le LQ Cancer Res; 2014 Jan; 74(2):586-97. PubMed ID: 24285727 [TBL] [Abstract][Full Text] [Related]
8. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153 [TBL] [Abstract][Full Text] [Related]
9. Calebin-A induced death of malignant peripheral nerve sheath tumor cells by activation of histone acetyltransferase. Lee MJ; Tsai YJ; Lin MY; You HL; Kalyanam N; Ho CT; Pan MH Phytomedicine; 2019 Apr; 57():377-384. PubMed ID: 30831486 [TBL] [Abstract][Full Text] [Related]
10. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628 [TBL] [Abstract][Full Text] [Related]
11. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448 [TBL] [Abstract][Full Text] [Related]
13. Knockdown of HMGA2 regulates the level of autophagy via interactions between MSI2 and Beclin1 to inhibit NF1-associated malignant peripheral nerve sheath tumour growth. Yang K; Guo W; Ren T; Huang Y; Han Y; Zhang H; Zhang J J Exp Clin Cancer Res; 2019 May; 38(1):185. PubMed ID: 31053152 [TBL] [Abstract][Full Text] [Related]
14. A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. Fernández-Rodríguez J; Creus-Bachiller E; Zhang X; Martínez-Iniesta M; Ortega-Bertran S; Guha R; Thomas CJ; Wallace MR; Romagosa C; Salazar-Huayna L; Reilly KM; Blakely JO; Serra-Musach J; Pujana MA; Serra E; Villanueva A; Ferrer M; Lázaro C Mol Cancer Ther; 2022 Jul; 21(7):1246-1258. PubMed ID: 35511749 [TBL] [Abstract][Full Text] [Related]
15. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. Subramanian S; Thayanithy V; West RB; Lee CH; Beck AH; Zhu S; Downs-Kelly E; Montgomery K; Goldblum JR; Hogendoorn PC; Corless CL; Oliveira AM; Dry SM; Nielsen TO; Rubin BP; Fletcher JA; Fletcher CD; van de Rijn M J Pathol; 2010 Jan; 220(1):58-70. PubMed ID: 19890883 [TBL] [Abstract][Full Text] [Related]
16. Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors. Amirnasr A; Verdijk RM; van Kuijk PF; Kartal P; Vriends ALM; French PJ; van Royen ME; Taal W; Sleijfer S; Wiemer EAC Sci Rep; 2020 Feb; 10(1):2927. PubMed ID: 32076030 [TBL] [Abstract][Full Text] [Related]
17. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165 [TBL] [Abstract][Full Text] [Related]
18. Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors. Cooper JM; Patel AJ; Chen Z; Liao CP; Chen K; Mo J; Wang Y; Le LQ Clin Cancer Res; 2019 Jun; 25(11):3404-3416. PubMed ID: 30796033 [TBL] [Abstract][Full Text] [Related]
19. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK. Ramkissoon A; Chaney KE; Milewski D; Williams KB; Williams RL; Choi K; Miller A; Kalin TV; Pressey JG; Szabo S; Azam M; Largaespada DA; Ratner N Clin Cancer Res; 2019 Jul; 25(13):4117-4127. PubMed ID: 30936125 [TBL] [Abstract][Full Text] [Related]